Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) for Patients With Hepatitis C Virus Infection: Real-world Effectiveness and Safety in Taiwan

NCT05092074 is registered in ClinicalTrials.gov with National Taiwan University Hospital as lead sponsor.

NCT NCT05092074
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05092074 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) for Patients With Hepatitis C Virus Infection: Real-world Effectiveness and Safety in Taiwan
Lead sponsor
National Taiwan University Hospital
Phase
Observational
Overall status
Unknown status
Start date
October 1, 2021
Completion date
February 28, 2023
Enrollment
100 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

adherence, treatment, effect of drug, hepatitis c virus infection, treatment side effects